Researchers from Walter and Eliza Hall Institute of Medical Research, The University of Melbourne and affiliated organizations presented the development of a new reporter mouse model designed to study the role of MDM2 and its transcriptional regulation in p53-mediated tumor suppression.
Prostate cancer is still one of the main causes of cancer death among men; while prostate-specific antigen (PSA) testing is done for screening, there are recommendations against its use due to its nonspecific and suboptimal results. There is thus an urgent need for new biomarkers that are more accurate in the detection of prostate cancer.
Previous research has shown that aberrant sphingolipid metabolism, which is evidenced by elevated levels of circulating ceramide, is associated with poor prognosis in patients with prostate cancer (PC). Work at the University of Adelaide has led to the establishment of a new syngeneic mouse model to study the role of sphingolipid metabolism in PC.
Researchers in from Nanjing Drum Tower Hospital have presented data from a study that investigated the role of immunoglobulin superfamily member 6 (IGSF6) microglia during ischemic stroke.
Microglia play a crucial role in neuroinflammation after ischemic brain injury. Previous data have shown that leukocyte immunoglobulin-like receptor B4 (LILRB4) was upregulated in mice after middle cerebral artery occlusion (MCAO), but the role it plays here is not well understood. The role LILRB4 plays in ischemic brain injury was thus investigated. LILRB4 expression was measured in mice at different time points after MCAO.
Ulcerative colitis is a chronic, immune-mediated disorder of the colon and rectum characterized by mucosal inflammation that damages the bowel wall surface. Current therapeutic options include 5-aminosalicylates, corticosteroids or anti-TNF agents, but there is a need for new strategies to obtain higher remission rates and less systemic immunosuppression.
Death receptor 3 (DR3) is the only signaling receptor for TNF superfamily ligand TL1A, the dysregulation of which has been implicated in multiple inflammatory diseases such as inflammatory bowel disease (IBD). Blockade of TL1A has been shown to induce significant clinical responses in IBD.
Mouse models for hemophilia A are commonly generated by factor VIII (FVIII) knockout, however, these mice rapidly develop anti-FVIII antibodies during repetitive FVIII administration. To overcome this preclinical research challenge, investigators from Octapharma AG and affiliated organizations developed a new model unable to produce antibodies but otherwise not immunosuppressed.
Researchers at E-Therapeutics plc recently presented efficacy and safety data on ETX-148, a pan-hemophilia agent in murine models of hemophilia A and B.
RSS
